APA
Popat U. R., Mehta R. S., Bassett R., Chen J., Valdez B. C., Kawedia J., Ahmed S., Alousi A. M., Anderlini P., Al-Atrash G., Bashir Q., Ciurea S. O., Hosing C. M., Im J. S., Jones R., Kebriaei P., Khouri I., Marin D., Nieto Y., Olson A., Oran B., Parmar S., Rezvani K., Qazilbash M. H., Shah N., Srour S. A., Shpall E. J., Champlin R. E. & Andersson B. S. (20181211). Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. : The Lancet. Haematology.
Chicago
Popat Uday R, Mehta Rohtesh S, Bassett Roland, Chen Julianne, Valdez Benigno C, Kawedia Jitesh, Ahmed Sairah, Alousi Amin M, Anderlini Paolo, Al-Atrash Geath, Bashir Qaiser, Ciurea Stefan O, Hosing Chitra M, Im Jin S, Jones Roy, Kebriaei Partow, Khouri Issa, Marin David, Nieto Yago, Olson Amanda, Oran Betul, Parmar Simrit, Rezvani Katayoun, Qazilbash Muzaffar H, Shah Nina, Srour Samer A, Shpall Elizabeth J, Champlin Richard E and Andersson Borje S. 20181211. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. : The Lancet. Haematology.
Harvard
Popat U. R., Mehta R. S., Bassett R., Chen J., Valdez B. C., Kawedia J., Ahmed S., Alousi A. M., Anderlini P., Al-Atrash G., Bashir Q., Ciurea S. O., Hosing C. M., Im J. S., Jones R., Kebriaei P., Khouri I., Marin D., Nieto Y., Olson A., Oran B., Parmar S., Rezvani K., Qazilbash M. H., Shah N., Srour S. A., Shpall E. J., Champlin R. E. and Andersson B. S. (20181211). Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. : The Lancet. Haematology.
MLA
Popat Uday R, Mehta Rohtesh S, Bassett Roland, Chen Julianne, Valdez Benigno C, Kawedia Jitesh, Ahmed Sairah, Alousi Amin M, Anderlini Paolo, Al-Atrash Geath, Bashir Qaiser, Ciurea Stefan O, Hosing Chitra M, Im Jin S, Jones Roy, Kebriaei Partow, Khouri Issa, Marin David, Nieto Yago, Olson Amanda, Oran Betul, Parmar Simrit, Rezvani Katayoun, Qazilbash Muzaffar H, Shah Nina, Srour Samer A, Shpall Elizabeth J, Champlin Richard E and Andersson Borje S. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. : The Lancet. Haematology. 20181211.